Contract research organizations make good money providing critical services to young biotech and drug development companies early on. But often, those companies are cash-strapped at the stage when they need a CRO. That’s why some CROs are becoming stakeholders in the companies they work with, offering cash or services for equity in life science startups.
“We fundamentally believe that we should be aligned with our clients,” said David Gee, strategic business development at Cato BioVentures, the venture capital affiliate of a CRO called Cato Research. “I think it’s reasonable, particularly with early-stage companies, that we have some skin in the game. (Then) we have reason to come to a positive endpoint and to get there as quickly and efficiently as possible, because that’s how part of our value is going to be generated.”